The trial, published in the journal Vaccines, utilized a SARS-CoV-2 Spike protein combined with the proprietary nOMV technology. Results showed that the vaccine was safe and well-tolerated, triggering dose-dependent systemic immune activity alongside protection at the nasal mucosa. This site-specific response is critical, as the upper respiratory tract serves as the primary entry point for many airborne pathogens that conventional injectable vaccines often fail to address effectively.

Anita Gashi, Managing Director of AdJane, noted that while current injectables excel at preventing severe disease, they remain limited in interrupting viral transmission. The company’s platform, derived from three decades of research at Dutch governmental institutions, uses Neisseria meningitidis vesicles to mimic bacterial structures. Beyond its performance in the Phase I trial, the technology offers practical advantages for global distribution, as the vaccine maintains stability under standard refrigeration for over 2.5 years, eliminating the need for ultra-cold supply chains.

AdJane is now leveraging these findings to advance a broader pipeline. This includes collaborations with CEPI for pandemic preparedness and a CARB-X-supported program targeting multidrug-resistant Neisseria gonorrhoeae. By utilizing a modular, plug-and-play design, the company aims to accelerate development cycles for emerging respiratory threats.